Serum platelet-activating factor acetylhydrolase activity: Relationship with metabolic syndrome in women with history of gestational diabetes mellitus

Gynecological Endocrinology

Volumn 27, Issue 2, 2011, Pages 128-133

  Derbent, Aysel ^a   Kargili, Ayse ^a   Koca, Cemile ^a   Gümüş, Ilknur Inegöl ^a   Sevgili, Sema ^a   Smavli, Serap ^a   Karakurt, Feridun ^a   Turhan, Nilgün Öztürk ^a  

^a FATIH UNIVERSITY MEDICAL SCHOOL   (Turkey)

Author keywords

gamma glutaminyl transferase; Gestational diabetes; metabolic syndrome; platelet activating factor acetylhydrolase

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; GLUCOSE; INSULIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; METABOLIC SYNDROME X; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; DIABETES, GESTATIONAL; FEMALE; HUMANS; METABOLIC SYNDROME X; PREGNANCY; PREVALENCE; REPRODUCTIVE HISTORY; TRIGLYCERIDES; YOUNG ADULT;

EID: 78651500448     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2010.487612     Document Type: Article

References (33)

1. Carpenter MW. Gestational diabetes, pregnancy hypertension, and late vascular disease. Diabetes Care 2007;30:246-250.
2. Di Benedetto A, Russo GT, Corrado F, Di Cesare E, Alessi E, Nicocia G, DAnna R, Cucinotta D. Inflammatory markers in women with a recent history of gestational diabetes mellitus. J Endocrinol Invest 2005;28:34-38.
3. Heitritter SM, Solomon CG, Mitchell GF, Skali-Ounis N, Seely EW. Subclinical inflammation and vascular dysfunction in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab 2005;90:3983-3988.
4. Negrato CA, Jovanovic L, Tambascia MA, Calderon IP, Geloneze B, Dias A. Mild gestational hyperglycaemia as a risk factor for metabolic syndrome in pregnancy and adverse perinatal outcomes. Diabetes Metab Res Rev 2008;24:324-330.
5. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342: 836-843.
6. Karasawa K. Clinical aspects of plasma platelet-activating factor-acetylhydrolase. Biochim Biophys Acta 2006;1761: 1359-1372.
7. Stafforini DM, McIntyre TM, Carter ME, Prescott SM. Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. J Biol Chem 1987;262:4215-4222.
8. Kudolo GB, Bressler P, DeFronzo RA. Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: effect of hyperinsulinemia and lovastatin treatment. J Lipid Mediat Cell Signal 1997;17:97-113.
9. Serban M, Tanaseanu C, Kosaka T, Vidulescu C, Stoian I, Marta DS, da Matta MF, Neves R, Tibiriça E. Significance of platelet-activating factor acetylhydrolase in patients with noninsulin- dependent (type 2) diabetes mellitus. J Cell Mol Med 2002;6:643-647.
10. Rizos E, Tambaki AP, Gazi I, Tselepis AD, Elisaf M. Lipoprotein- associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome. Prostaglandins Leukot Essent Fatty Acids 2005;72:203-209.
11. 1979 National Diabetes Data Group Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-1057.
12. National Cholesterol Educational Program 2001. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
13. Mathews DR, Hosker JP, Rudenski AS, Naylor BA Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
14. Aarsman AJ, Neys FW, Van den Bosch H. Catabolism of platelet-activating factor and its acyl analog. Differentiation of the activities of lysophospholipase and platelet-activatingfactor acetylhydrolase. Eur J Biochem 1991;200:187-193.
15. Gomes MB, Cobas RA, Nunes E, Castro-Faria-Neto HC, da Matta MF, Neves R, et al. Plasma PAF-acetylhydrolase activity, inflammatory markers and susceptibility of LDL to in vitro oxidation in patients with type 1 diabetes mellitus. Diabetes Res Clin Pract 2009;85:61-68.
16. Tselepis AD, Dentan C, Karabina SA, Chapman MJ, Ninio E. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma: catalytic characteristics and relation to the monocyte derived enzyme. Artherioscler Thromb Vasc Biol 1995;15:1764-1773.
17. Macphee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA, Leake DS, Milliner KJ, Patterson RA, Suckling KE, et al. Lipoprotein-associated phospholipase A2, plateletactivating factor acetylhydrolase, generates two bioactive products during the oxidation of low density lipoprotein: studies using a novel inhibitor. Biochem J 1999;338:479-487.
18. Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH. Lipoprotein-associated phospholipase A2, platelet-activating factor acetyhydolase: a potential new risk factor for coronary artery disease. Atherosclerosis 2000;150:413-419.
19. Yamada Y, Yoshida H, Ichihara S, Imaizumi T, Satoh K, Yokota M. Correlation between plasma plateletactivating factor (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. Atherosclerosis 2000;150:209-216.
20. Blankenberg S, Stengel D, Rupprecht HJ, Bickel C, Meyer J, Cambien F, Tiret L, Ninio E. Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a crosssectional analysis. J Lipid Res 2003;44:1381-1386.
21. Winkler K, Winkelmann BR, Scharnagl H, Hoffmann MM, Grawitz AB, Nauck M, Böhm BO, Marz W. Plateletactivating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study. Circulation 2005;111:980-987.
22. Howard KM, Miller JE, Miwa M, Olson MS. Cell-specific regulation of expression of plasma-type platelet-activating factor acetylhydrolase in the liver. J Biol Chem 1997;272: 27543-27548.
23. Stafforini DM, Elstad MR, McIntyre TM, Zimmerman GA, Prescott SM. Human macrophages secret plateletactivating factor acetylhydrolase. J Biol Chem 1990;265:9682-9687.
24. Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, Mc Intyre TM, Du BN, Fagelman AM, Berliner JA. Effect of platelet-activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 1995;95:774-782.
25. Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev 2006;22:423-436.
26. Yoshida H, Satoh K, Imaizumi T. Activity of plateletactivating factor acetylhydrolase exists in red cell membrane. Am J Hematol 1992;40:61-63.
27. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-169.
28. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985;61:946-951.
29. Nakanishi N, Suzuki K, Tatara K. Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care 2004;27:1427-1432.
30. Talbott EO, Zborwski JV, Rager JR, Boudreaux MY, Edmndowicz DA, Guzick DS. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:5454-5461.
31. Jousilahti P, Rastenyte D, Tuomilehto J. Serum g-glutamyl transferase, self-reported alcohol drinking, and the risk of stroke. Stroke 2000;31:1851-1855.
32. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, OReilly DS, Packard CJ, Sattar N. West of Scotland Coronary Prevention Study. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002;51:1596-1600.
33. Festa A, DAgostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-47